The global aortic stenosis market size was valued at nearly USD 5.4 Billion in 2022 and is expected to reach USD 12.6 Billion by 2031, expanding at a CAGR of 9.8% during the forecast period, 2023 – 2031. The growth of the market is attributed to the growing numbers of aortic stenosis and valvular heart diseases in the geriatric population.
Aortic stenosis is a valvular heart disease with varying severity. Narrowed valve openings of the large blood vessel aorta reduce blow flow making the heart pump excessively. Poor prognosis with a fatal mortality rate is observed in severe cases. In-time diagnosis and treatment are of significant importance.
Congenital heart defects, rheumatic fever, and the building up of excess calcium in the heart valves are some of the known causes of aortic stenosis. Chest pain, fainting, fatigue, abnormal heart beats, and sound are commonly observed symptoms. Heart attack diagnostics is a suitable method to check for heart abnormalities.
The market report finds that the COVID-19 pandemic adversely affected the aortic stenosis market growth with sudden government-imposed lockdowns around the world. There was a large decline in Transcatheter Aortic Valve Implantation (TAVI) and Surgical Aortic Valve Replacement (SAVR) procedural activity for treating severe aortic stenosis cases during the COVID-19 pandemic.
Major Drivers
Growing geriatric population with heart valve abnormalities is driving the market growth of the aortic stenosis market. Health complications involving severe diabetes and obesity are major causes for an increased number of aortic stenosis patients. Extensive research and innovation of effective drugs to counter the disease are expected to bolster the aortic market development in the near future.
Existing Restraints
High treatment costs and complex treatment procedures are likely to restrain market growth in the coming years. Reactive nature of treatments available is a major hindrance for the widespread expansion of the aortic stenosis market.
Emerging Opportunities
Improving healthcare facilities and introducing of innovative healing methods are providing growth opportunities for market expansion. Growing adoption of initiatives for spreading awareness about treatments, symptoms, and causes of aortic stenosis coupled with investments in healthcare are expected to increase market development opportunities for the aortic stenosis market in the forecast period.
Scope of Aortic Stenosis Market Report
The market report includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
|
Attributes
|
Details
|
|
Report Title
|
Aortic Stenosis Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast
|
|
Base Year
|
2022
|
|
Historic Data
|
2020 – 2021
|
|
Forecast Period
|
2023–2031
|
|
Segmentation
|
Type (Congenital [Subvalvular, Valvular, and Supravalvular] and Acquired), Treatment (Transcatheter Aortic Valve Implantation and Surgical Aortic Valve Replacement), and Treatment Center (Pharmacy Stores, Clinics, and Hospitals)
|
|
Regional Scope
|
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa
|
|
Report Coverage
|
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast
|
|
Key Players Covered in the Report
|
Boston Scientific Corporation; CryoLife, Inc.; JenaValve Technology, Inc.; Thubrikar Aortic Valve; Medtronic plc; Coroneo Meril Life Sciences Pvt. Ltd.; AstraZeneca plc.; Abbott Laboratories; LivaNova PLC; Edwards Lifesciences Corporation; and LifeNet Health.
|
Aortic Stenosis Market Segment Insights
Type Segment Analysis
Based on the type, the aortic stenosis market is bifurcated into congenital aortic stenosis and acquired aortic stenosis. The congenital aortic stenosis segment is projected to hold a considerable CAGR during the forecast period, due to the presence of abnormalities in children by birth due to genetically induced conditions.
The congenital aortic stenosis segment is further subclassified based on the level of stenosis, into subvalvular aortic stenosis, valvular, and supravalvular aortic stenosis, and is known to develop during the first 8 weeks of pregnancy. Subvalvular aortic stenosis defects are known to be formed during fetal development and are linked with several congenital syndromes. Structural heart imaging techniques are useful to some extent in the early diagnosis of aortic valve stenosis.
The acquired aortic stenosis segment is anticipated to hold a key share of the market, owing to the increasing cases of diabetes, high blood pressure, abnormal lipids, and chronic kidney diseases in the mid-aged population. Increasing stress levels may complicate aortic stenosis conditions which are known to be progressive disease-causing conditions.
Treatment Segment Analysis
On the basis of the treatment, the market is divided into transcatheter aortic valve implantation (TAVI) and surgical aortic valve replacement (SAVR). The transcatheter aortic valve implantation treatment technique is anticipated to rise significantly in the coming years of the forecast period, owing to the non-invasive nature of the treatment.
The recovery time for patients post transcatheter aortic valve implantation (TAVI) is less in comparison to other treatments which is expected to boost the segment. The surgical aortic valve replacement (SAVR) segment is anticipated to account for a major market share in the coming years, owing to the surgical nature of the treatment carried out by specialized surgeons.
For patients with high surgical risk, surgical aortic valve replacement (SAVR) is a clinically effective heart valve replacement treatment option that is expected to boost the segment during the forecast period.
Treatment Center Segment Analysis
Based on the treatment center, the aortic stenosis market is subdivided into pharmacy stores, clinics, and hospitals. The hospitals segment is expected to expand at a significant growth rate during the projection period owing to the complications involved in open surgeries that need specialization and are time-consuming.
Hospitals are well equipped with the latest technologies and highly skilled doctors to perform necessary medical tasks for taking care of suffering patients which is expected to boost the market share in the next few years.
The retail pharmacy segment is anticipated to account for a major market share in the coming years, owing to the pharmaceutical dispensing facilities of prescribed drugs and devices in moderate quantities. Drugs are stored, dispensed, and compounded with filled prescriptions effective for aortic stenosis treatments which are likely to boost the segment growth in the forecast period.
Regional Analysis
In terms of region, the global aortic stenosis market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is expected to dominate the market during the projection period, owing to the rising cases of aortic stenosis, growing healthcare expenses, and increased awareness about aortic stenosis, in North America. Close to 5% of the total American population, is suffering from aortic stenosis who are above 85 years of age.
Asia Pacific is projected to grow at a rapid pace in the forecast period, owing to advancements in the healthcare sector of Japan, India, and China in specific. Growing government initiatives for promoting awareness about aortic stenosis and a rise in the demand for treatment options are some of the other factors expected to increase revenue in the Asia Pacific region.
Segments
The global aortic stenosis market has been segmented on the basis of
Type
- Congenital
- Subvalvular
- Valvular
- Supravalvular
- Acquired Aortic Stenosis
Treatment Center
- Pharmacy Stores
- Clinics
- Hospitals
End-user
- Online Pharmacy
- Retail Pharmacy
- Hospital Pharmacy
Region
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
Key Players
- Boston Scientific Corporation
- CryoLife, Inc.
- JenaValve Technology, Inc.
- Thubrikar Aortic Valve
- Medtronic plc
- Coroneo; Meril Life Sciences Pvt. Ltd.
- AstraZeneca plc.
- Abbott Laboratories
- LivaNova PLC
- Edwards Lifesciences Corporation
- LifeNet Health
Competitive Landscape
Key players competing in the aortic stenosis market are Boston Scientific Corporation; CryoLife, Inc.; JenaValve Technology, Inc.; Thubrikar Aortic Valve; Medtronic plc; Coroneo Meril Life Sciences Pvt. Ltd.; AstraZeneca plc.; Abbott Laboratories; LivaNova PLC; Edwards Lifesciences Corporation; and LifeNet Health.
These companies adopted development strategies including mergers, acquisitions, partnerships, collaboration, product launches, and production expansion to expand their consumer base worldwide. The competitive landscape covers key insights into growth strategies adopted by major market players.
-
In September 02, 2020, CryoLife, a leading manufacturing company of medical devices, announced the acquisition of aortic repair device developer Ascyrus Medical known for developing the world’s first aortic arch remodeling device for treating acute Type A aortic dissections. The deal was valued at up to USD 200 Mn between the giants of the medical manufacturing industry.
Request For Customization
Enquiry Before Buying
Speak With Analyst
